GlassScriptPhysician profile
Tiffany D Crites
NPI 1043030513
$1,328.46
in general payments reported to CMS, 2019-2025
20 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $251 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.48 |
| Education | $287.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $152.69 | 2025 | Imfinzi, Enhertu |
| Exelixis INC. | $142.77 | 2024-2025 | Cabometyx |
| Astellas Pharma US INC | $129.55 | 2025 | Xtandi, Padcev |
| Stemline Therapeutics INC. | $124.44 | 2024 | Orserdu |
| Glaxosmithkline, LLC. | $118.89 | 2025 | Jemperli, Zejula |
| Seagen INC. | $92.99 | 2025 | |
| Merck Sharp & Dohme LLC | $87.48 | 2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $83.38 | 2025 | Balversa, Erleada, Tecvayli |
| Daiichi Sankyo INC. | $65.49 | 2025 | Enhertu, Datroway |
| Sumitomo Pharma America, INC. | $58.70 | 2025 | Orgovyx |
| Lilly USA, LLC | $43.77 | 2025 | Jaypirca, Verzenio |
| Beone Medicines USA, INC. | $41.87 | 2025 | Brukinsa |
| Incyte Corporation | $41.44 | 2025 | Jakafi, Monjuvi |
| Legend Biotech USA INC. | $25.77 | 2025 | Carvykti |
| Novartis Pharmaceuticals Corporation | $23.77 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $23.37 | 2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $21.05 | 2025 | |
| Eisai INC. | $19.66 | 2025 | |
| Dendreon Pharmaceuticals LLC | $16.98 | 2024 | Provenge |
| Shield Therapeutics INC | $14.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Crites listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.